Gates Biomanufacturing Facility Announces Strategic Manufacturing Partnership with Cell Therapy Pioneer, Nkarta

The Gates Biomanufacturing Facility signed a continued strategic agreement with Nkarta to manufacture clinical supply of therapeutic Natural Killer cells. As part of this collaboration, GBF will continue to manufacture NKX101, an immunotherapy currently in a Phase I clinical trial for patients with relapsed/refractory acute myeloid leukemia or higher-risk myelodysplastic syndromes.